Clinical trial NCT04707703: Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
Official title: Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
Aspergillosis Invasive
Keywords: Isavuconazole
Antifungal Agents
Anti-infective Agents
Coronavirus-associated Invasive Pulmonary Aspergillosis
CAPA
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
Collaborators: name: Astellas Pharma Global Development, Inc.
First posted: 2021-01-13
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study is to evaluate whether antifungal prophylaxis with isavuconazole can reduce the incidence of SARS-CoV-2-associated invasive aspergillosis in patients in the ICU (intensive care unit) with severe COVID-19 infection.

The investigators will perform an interventional, double-blinded, randomized-controlled, multi-center study in patients with severe COVID-19 infection admitted to the ICU. Patients will be randomized to the isavuconazole prophylaxis plus standard of care (SOC) group or the placebo plus SOC group. Participants will receive isavuconazole or placebo for up to 28 days or until discharge from the hospital (whichever occurs first).

Detailed description: Adult patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 (COVID-19) infection without a diagnosis of invasive aspergillosis who are hospitalized in the ICU are eligible for inclusion in this study and will be randomized to the isavuconazole plus standard of care (SOC) group or placebo plus SOC group.

If randomized to the isavuconazole group, participants will receive intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days. If randomized to the placebo group, participants will receive intravenous placebo every 8 hours for 6 doses followed by once daily for up to 28 days. Both groups will receive the usual SOC.

Following randomized to the two treatment arms, participants will be screened for invasive aspergillosis with thrice weekly fungal cultures from tracheal aspirate (TA) secretions or thrice weekly serum galactomannan (GM) testing (if TA unable to be performed, contraindicated, or participant is not intubated). If invasive aspergillosis or other invasive fungal infection is detected, antifungal therapy will be initiated (if the participant is in the placebo arm) or modified if needed (if the participant is in the isavuconazole arm).

Eligibility criteria: Inclusion Criteria:

* Written informed consent obtained from the patient or his/her legally authorized person.
* Adult patient (\> 18 years).
* PCR-confirmed SARS-CoV-2 based on nasopharyngeal swab (NPS), oropharyngeal swab (OPS), tracheal aspirate (TA), bronchial aspirate (BA), or bronchoalveolar lavage fluid (BALF) within 14 days prior to ICU admission or within 72 hours following ICU admission.
* Radiographic imaging consistent with SARS-CoV-2 infection (e.g. atypical pneumonia, organizing pneumonia, ground glass opacities) or acute respiratory distress syndrome (ARDS) within 7 days of diagnosis of SARS-CoV-2 infection.
* A negative pregnancy test in women of child-bearing age.
* If a woman is of child-bearing age, she must be willing to use an effective method of contraception for 28 days after the final dose of isavuconazole per manufacturer instructions

Exclusion Criteria:

* Anticipated transfer to another medical center that is not a study site within hours of admission to the ICU.
* Pregnancy based on a positive human chorionic gonadotropin (HCG) test from serum or urine.
* Patient who is breastfeeding and unable to discontinue breastfeeding while taking the study drug.
* Patients with a diagnosis of invasive aspergillosis/detection of Aspergillus spp. by culture from sputum, TA, BA, or BALF or positive GM from serum or BALF at time of screening or randomization.
* History of invasive aspergillosis within the prior six months.
* Patients with a known intolerance or hypersensitivity to isavuconazole or other azole agents.
* History of familial short QT syndrome.
* Patients that are being treated with mold-active antifungal agents for invasive aspergillosis or another invasive fungal infection.
* Patients with severe hepatic impairment or liver cirrhosis (Child C) should be excluded from the study unless the treating physicians feel the benefits of treatment outweigh the risks.
* Treatment with Lopinavir/ritonavir for HIV infection.
* Prohibited Medications
* Co-administration with a strong CYP3A4 inhibitor or high-dose ritonavir as they may alter the plasma concentration of isavuconazole.
* Co-administration with a strong CYP3A4 inducer such as rifampin, carbamazepine, St. John's wort, or long acting barbiturates.

Primary outcomes:
measure: The incidence of SARS-CoV-2-associated invasive aspergillosis at time of ICU discharge
timeFrame: From date of admission in ICU assessed up to ICU discharge, approximately 28 days
Secondary outcomes:
measure: The incidence of SARS-CoV-2-associated non-Aspergillus invasive fungal infections at time of ICU discharge
timeFrame: From date of admission in ICU assessed up to ICU discharge, approximately 28 days
measure: Survival
timeFrame: From date of admission in ICU assessed up to ICU discharge, approximately 28 days
measure: Length of ICU stay
timeFrame: From date of admission in ICU assessed up to ICU discharge, approximately 28 days
measure: Length of Hospital stay
timeFrame: From date of admission in ICU assessed up to hospital discharge, approximately 32 days
measure: Mortality
timeFrame: At 30 and 90 days
measure: Adverse events
timeFrame: From date of start of isavuconazole or placebo through duration of isavuconazole or placebo, approximately 28 days
Other outcomes:
Locations:
city: Orange
country: United States
facility: University of California Irvine
state: California
city: Sacramento
country: United States
facility: University of California Davis
state: California
city: San Diego
country: United States
facility: University of California San Diego
state: California
Study officials:
affiliation: University of California, San Diego
name: Jeffrey Jenks, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, Davis
name: George Thompson, MD
role: STUDY_CHAIR
affiliation: University of California, San Diego
name: Martin Hoenigl, MD
role: STUDY_CHAIR
References: